Skip to main content
Premium Trial:

Request an Annual Quote

Melanie Mahtani, Kevin King

Melanie Mahtani has been named executive advisor of commercial development at Med BioGene.
Mahtani was most recently vice president of corporate business development at Panomics where she led the company's strategic partnering activities with diagnostics, pharmaceutical, and biotechnology companies. Before Panomics, Mahtani served as director of microarray systems R&D at Amersham Biosciences and as vice president of business development and scientific collaboration at Genospectra.
Mahtani holds a PhD in genetics from Stanford University.

Affymetrix has promoted Kevin King to president of the company from his previous post as vice president of life sciences and executive vice president. King joined Affy in January of this year. Prior to that, he was CEO and president of Thomson Healthcare and also held executive-level roles at GE Healthcare and Hewlett-Packard.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.